|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
2018
merger
Neotope Biosciences
|
|
gptkbp:CEO
|
gptkb:Gene_Kinney
|
|
gptkbp:clinicalTrials
|
gptkb:Canada
gptkb:United_States
Europe
Phase 1
Phase 2
Phase 3
PRX002
PRX003
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
|
|
gptkbp:focus
|
neurodegenerative diseases
|
|
gptkbp:founded
|
2012
|
|
gptkbp:founder
|
gptkb:Christoph_Westphal
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prothena Corporation
|
|
gptkbp:investmentFocus
|
2013
various venture capital firms
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:mission
|
develop innovative therapies
|
|
gptkbp:numberOfEmployees
|
51-200
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
strategic partnership
|
|
gptkbp:patentCitation
|
multiple patents in biotechnology
|
|
gptkbp:products
|
PRX004
PRX002
PRX003
|
|
gptkbp:research
|
public and private funding
|
|
gptkbp:researchAreas
|
monoclonal antibodies
biologics
therapeutics
|
|
gptkbp:researchFocus
|
Alzheimer's disease
Amyloidosis
Parkinson's disease
|
|
gptkbp:stockSymbol
|
PRTA
|
|
gptkbp:subsidiary
|
gptkb:Prothena_Biosciences
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:vision
|
transforming the treatment of neurodegenerative diseases.
|
|
gptkbp:website
|
www.prothena.com
|